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[57] ABSTRACT 
A hybrid vector carrying a ?rst and second DNA segments 
operationally linked thereto, the ?rst DNA segment encod 
ing a protein capable of cross-linking to the cap structure of 
mRNA and mediating ribosome-binding, and the second 
DNA segment encoding a polypeptide or protein. the vector 
being capable of replication, transcription and translation to 
express the factor and the polypeptide or protein upon 
transformation of a eukaryotic host. and the polypeptide or 
protein being expressed at a level higher than the level of 
expression thereof in the absence of the ?rst DNA segment. 
A eukaryotic host is transformed with this hybrid vector. 
Also disclosed is a method of increasing the synthesis of a 
polypeptide or protein in a eukaryotic host cell. 
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